In fact, the complement system is defective in chronic lymphatic leukemia patients.[46] From a translational perspective, it is imperative to dissect the versatile role of complement‐mediated tumor progression and immune modulation in KRAS‐driven and MYC‐driven cancers. This evidence concerns the gene KRAS and B-cell chronic lymphocytic leukemia.